Cipla Ltd. logo

Cipla Ltd. (CIPLA)

Market Closed
8 Jun, 22:00
MSE MSE
1,392. 30
-8.4
-0.5997%
- Market Cap
- P/E Ratio
52% Div Yield
28,778 Volume
- Eps
1,400.7
Previous Close
Add Transaction
Day Range
1,389.3 1,404.9
Year Range
1,165.55 1,672.2
Want to track CIPLA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CIPLA closed Monday lower at ₹1,392.3, a decrease of -0.5997% from Friday's close, completing a monthly decrease of -0.9039% or -₹12.7. Over the past 12 months, CIPLA stock lost -7.6326%.
CIPLA pays dividends to its shareholders, with the most recent payment made on Aug 15, 2025. The next announced payment will be in In 1 week on Jun 20, 2026 for a total of ₹13.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -1.41%, based on the last three reports.
Cipla Ltd. has completed 2 stock splits, with the recent split occurring on Apr 24, 2006.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on MSE (INR).

CIPLA Chart

Cipla Ltd. (CIPLA) FAQ

What is the stock price today?

The current price is ₹1,392.30.

On which exchange is it traded?

Cipla Ltd. is listed on MSE.

What is its stock symbol?

The ticker symbol is CIPLA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 52%.

What is its market cap?

As of today, no market cap data is available.

Has Cipla Ltd. ever had a stock split?

Cipla Ltd. had 2 splits and the recent split was on Apr 24, 2006.

Cipla Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Umang Vohra B.E., M.B.A. CEO
MSE Exchange
INE059A01026 ISIN
India Country
27,764 Employees
5 Jun 2026 Last Dividend
24 Apr 2006 Last Split
- IPO Date

Overview

Cipla Limited is a comprehensive pharmaceutical company established in 1935, with a primary focus on manufacturing, development, sale, and distribution of pharmaceutical products. With its headquarters in Mumbai, India, Cipla has expanded its reach internationally, actively operating in the United States, South Africa, and various other global markets. The company's business operations are segmented into Pharmaceuticals and New Ventures, highlighting its diverse interest in the healthcare and pharmaceutical industry. Cipla's commitment to healthcare is evident through its extensive range of products and involvement in consumer healthcare, biosimilars, and specialty businesses, aiming to address a broad spectrum of therapeutic areas and medical needs globally.

Products and Services

  • Generic and Branded Generic Medicines

    Cipla offers a comprehensive portfolio of generic and branded generic medicines, making essential drugs more accessible and affordable to the global population. These medicines cover a wide range of therapeutic areas, including but not limited to cardiovascular diseases, respiratory conditions, and diabetes management.

  • Vaccines

    The company contributes to public health by providing vaccines, which are crucial for preventing infectious diseases and promoting health and wellness across various communities around the world.

  • Active Pharmaceutical Ingredients (APIs)

    Cipla manufactures and supplies high-quality active pharmaceutical ingredients, serving as the backbone for producing effective and safe medications. These APIs are critical for the development of a wide array of pharmaceutical products.

  • Formulations

    With expertise in pharmaceutical formulation, Cipla develops and distributes a range of formulations designed to treat numerous health conditions effectively, from chronic diseases like Alzheimer's and heart disease to acute conditions such as infections and critical care needs.

  • Consumer Healthcare

    Beyond prescription medicines, Cipla is also involved in the consumer healthcare sector, offering over-the-counter (OTC) products that address everyday health concerns, including nutritional supplements and personal care items.

  • Biosimilars

    Investing in the future of biologic medicines, Cipla engages in the development and distribution of biosimilars. These products offer similar efficacy to original biologics, providing more affordable treatment options for patients.

  • Specialty Businesses

    Focusing on niche therapeutic areas, Cipla's specialty businesses concentrate on developing and commercializing advanced treatments for complex conditions, such as oncology and neuro psychiatry, underscoring the company's dedication to tackling challenging healthcare issues.

Contact Information

Address: Cipla House
Phone: 91 22 2482 6000